Supplemental Figure 9. Combination activity of cobimetinib and GDC-0994 in a BRAF and NRAS mutant melanoma xenograft model. (a) A375.X1 (BRAFV600E, melanoma) tumor xenograft bearing animals (n=10/group) were treated with vehicle, cobimetinib (3 mg/kg, PO, QD), GDC-0994 (30 mg/kg, PO, QD) or the combination for 21 days and tumor growth and body weights were measured. Group mean tumor volume and body weights are plotted ± SEM. (b) IPC-298 (NRASQ61L, melanoma) tumor xenograft bearing animals (n=10/group) were treated with vehicle, cobimetinib (5 mg/kg, PO, QD), GDC-0994 (60 mg/kg, PO, QD) or the combination for 21 days and tumor growth and body weights were measured. Group mean tumor volume and body weights are plotted ± SEM. Groups achieving statistical significance are shown (Students t-test, ** p<0.005, *** p<0.001, **** p<0.0001).